SNDX (Syndax Pharmaceuticals, Inc.) Stock Financials & Earnings

SNDXSyndax Pharmaceuticals, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$172M

Net Income (TTM)-$285M

EPS (TTM)-$3.30

Free Cash Flow (TTM)-$323M

Gross Margin96.0%

Op. Margin-158.4%

Net Margin-165.6%

FCF Margin-187.5%

P/S Ratio (TTM)12.5x

P/E Ratio (TTM)—

YoY Rev Growth+627.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$46M
Q2 23	$0	$0	-$50M
Q3 23	$0	$0	-$56M
Q4 23	$0	$0	-$78M
Q1 24	$0	$0	-$80M
Q2 24	$4M	$4M	-$74M
Q3 24	$13M	$13M	-$90M
Q4 24	$8M	$8M	-$96M
Q1 25	$20M	$19M	-$84M
Q2 25	$38M	$37M	-$69M
Q3 25	$46M	$39M	-$57M
Q4 25	$68M	$70M	-$63M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$34M	$12M	—
Q2 23	$35M	$15M	—
Q3 23	$39M	$17M	—
Q4 23	$55M	—	$23M
Q1 24	$56M	$23M	—
Q2 24	$49M	$29M	—
Q3 24	$71M	$31M	—
Q4 24	$66M	$38M	—
Q1 25	$62M	$41M	—
Q2 25	$62M	$44M	—
Q3 25	$56M	—	$45M
Q4 25	$79M	$50M	—

Revenue Segments

Quarter	Collaboration revenue	Product
Q2 25	$9M	$29M
Q3 25	$14M	$32M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$58M	$375M	$432M
Q2 23	$97M	$309M	$406M
Q3 23	$95M	$269M	$364M
Q4 23	$295M	$282M	$578M
Q1 24	$115M	$320M	$435M
Q2 24	$105M	$320M	$425M
Q3 24	$133M	$257M	$390M
Q4 24	$154M	$429M	$583M
Q1 25	$154M	$362M	$516M
Q2 25	$109M	$360M	$469M
Q3 25	$117M	$337M	$454M
Q4 25	$135M	$259M	$394M

Shares Outstanding

Revenue Per Employee

Revenue / Employee